Skip to main content

Table 1 Baseline characteristics of the patients

From: Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis

Characteristics Overall (n = 401) Genotype 1 (n = 315) Genotype 2 (n = 86 )
Male sex, n (%) 170 (42.4%) 132 (41.9%) 38 (44.2%)
Age, median years (range) 67 (22–87) 68 (31–87) 65 (22–84)
Cirrhosis, n (%) 89 (22.2%) 75 (23.8%) 14 (16.3%)
Treatment experienced, n (%) 123 (30.7%) 110 (34.9%) 13 (15.1%)
HCV RNA, log IU/mL, median (range) 6.1 (2.0–7.5) 6.1 (2.0–7.5) 5.9 (3.0–7.2)
Albumin, g/dL, median (range) 4.1 (2.6–4.9) 4.1 (2.6–4.9) 4.1 (2.9–4.8)
Total bilirubin, mg/dL, median (range) 0.7 (0.2–28.1) 0.7 (0.2–28.1) 0.7 (0.2–2.4)
AST, IU/L, median (range) 41 (10–360) 42 (10–360) 38 (14–250)
ALT, IU/L, median (range) 42 (5–382) 42 (8–382) 40 (5–251)
Platelets, ×104/mm3, median (range) 14.6 (0.6–55.2) 14.6 (0.6–55.2) 14.4 (4.0–30.0)
Prothrombin time, %, median (range) 90.0 (16.3–134.2) 90.3 (20.4–134.2) 86.9 (16.3–121.1)
Hemoglobin, g/dL, median (range) 13.4 (1.1–18.4) 13.4 (1.1–17.0) 13.5 (9.1–18.4)
NS5A resistance associated variantsa, n (%)
 Neither L31 or Y93 184 (58.4%)
 Either L31 or Y93 40 (12.7%)
 Both L31 and Y93 2 (0.6%)
Treatment agents, n (%)
 DCV+ASV 110 (27.4%) 110 (34.9%) 0 ( 0%)
 SOF/LDV 184 (45.9%) 184 (58.4%) 0 ( 0%)
 OBV/PTV/r 10 ( 2.5%) 10 ( 3.2%) 0 ( 0%)
 EBR+GZR 11 ( 2.8%) 11 ( 3.5%) 0 ( 0%)
 SOF+RBV 85 (21.2%) 0 ( 0%) 85 (98.8%)
 OBV/PTV/r+RBV 1 ( 0.2%) 0 ( 0%) 1 ( 1.2%)
  1. aEighty-nine patients treated with SOF/LDV were not checked
  2. AST Aspartate aminotransferase, ALT Alanine aminotransferase, NS5A Nonstructural protein 5A, DCV Daclatasvir, ASV Asunaprevir, SOF Sofosbuvir, LDV Ledipasvir, OBV Ombitasvir, PTV Paritaprevir, r Ritonavir, EBR Elbasvir, GZR Grazoprevir and RBV Ribavirin